Alnylam First Quarter 2022 Financial Results; Cuts Guidance

 − Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO^®, GIVLAARI^®, and OXLUMO^® –

− Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy –

− Announced 3-Month Extension of Review Period for New Drug Application for Vutrisiran due to Amendment to Address Pending Inspection Classification at Third-Party Secondary Packaging and Labeling Facility –

– Decreased 2022 Guidance Range for Combined Net Product Revenues from $900 Million – $1 Billion to $870 – $930 Million –

https://www.biospace.com/article/releases/alnylam-pharmaceuticals-reports-first-quarter-2022-financial-results-and-highlights-recent-period-activity/